Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2 - and TET2 -Mutant Acute Myeloid Leukemia
2017; American Association for Cancer Research; Volume: 7; Issue: 5 Linguagem: Inglês
10.1158/2159-8290.cd-16-1049
ISSN2159-8290
AutoresAlan H. Shih, Cem Meydan, Kaitlyn Shank, Francine E. Garrett-Bakelman, Patrick S. Ward, Andrew M. Intlekofer, Abbas Nazir, Eytan M. Stein, Kristina M. Knapp, Jacob L. Glass, Jeremy Travins, Kim Straley, Camelia Gliser, Christopher E. Mason, Katharine Yen, Craig B. Thompson, Ari Melnick, Ross L. Levine,
Tópico(s)Histone Deacetylase Inhibitors Research
ResumoGenomic studies in acute myeloid leukemias (AML) have identified mutations that drive altered DNA methylation, including
Referência(s)